MAPT and Alzheimer disease: FSD-C10 showed therapeutic potential in AD mouse model, possibly through inhibiting the formation of Aβ42 and phosphorylation of tau and promoting the generation of synapse-associated proteins and neurotrophic factors (Li et al., 2017; Gu et al., 2018).